Specific immunotherapy in ovarian cancer: a systematic review

Immunotherapy. 2016 Oct;8(10):1193-204. doi: 10.2217/imt-2016-0034.

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Several approaches of active and passive immunotherapy for EOC have been studied. The aim of this systematic review was to assess the clinical efficacy of specific immunotherapy in patients with EOC. We found 4524 references in seven databases and we included ten controlled clinical trials with 2285 patients with EOC reporting five active immunotherapeutic agents and three passive immunotherapies. Meta-analysis of six studies showed that overall there was not any significant difference in overall survival and recurrence-free survival between patients undergoing specific immunotherapy and those in control group. Most of the studies we evaluated reported a positive outcome from treatment with specific immunotherapy, although this was not significant.

Keywords: active immunotherapy; clinical outcome; immunotherapy; meta-analysis; ovarian cancer; passive immunotherapy; systematic review; vaccines.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Carcinoma, Ovarian Epithelial
  • Clinical Trials as Topic
  • Female
  • Humans
  • Immunotherapy*
  • Neoplasms, Glandular and Epithelial / immunology
  • Neoplasms, Glandular and Epithelial / mortality
  • Neoplasms, Glandular and Epithelial / therapy*
  • Ovarian Neoplasms / immunology
  • Ovarian Neoplasms / mortality
  • Ovarian Neoplasms / therapy*
  • Survival Analysis
  • Treatment Outcome